We are live on ! Find out more
NVS icon

Novartis

1,087 hedge funds and large institutions have $23.4B invested in Novartis in 2018 Q4 according to their latest regulatory filings, with 143 funds opening new positions, 342 increasing their positions, 403 reducing their positions, and 76 closing their positions.

New
Increased
Maintained
Reduced
Closed

88% more first-time investments, than exits

New positions opened: 143 | Existing positions closed: 76

82% more funds holding in top 10

Funds holding in top 10: 2240 (+18)

34% more call options, than puts

Call options by funds: $108M | Put options by funds: $80.5M

6% more funds holding

Funds holding: 1,0281,087 (+59)

4% more capital invested

Capital invested by funds: $22.4B → $23.4B (+$988M)

0.53% more ownership

Funds ownership: 11.4%11.93% (+0.53%)

15% less repeat investments, than reductions

Existing positions increased: 342 | Existing positions reduced: 403

Holders
1,087
Holders Change
+59
Holders Change %
+5.74%
% of All Funds
24.22%
Holding in Top 10
40
Holding in Top 10 Change
+18
Holding in Top 10 Change %
+81.82%
% of All Funds
0.89%
New
143
Increased
342
Reduced
403
Closed
76
Calls
$108M
Puts
$80.5M
Net Calls
+$27.4M
Net Calls Change
+$1.61M
Name Holding Trade Value Shares
Change
Change in
Stake
SCCM
26
Schafer Cullen Capital Management
New York
$206M -$17.9M -229,652 -8%
PPA
27
Parametric Portfolio Associates
Washington
$205M +$24.7M +317,655 +14%
Dimensional Fund Advisors
28
Dimensional Fund Advisors
Texas
$196M +$1.38M +17,726 +0.7%
FWIA
29
Fort Washington Investment Advisors
Ohio
$167M -$6.46M -82,992 -4%
EARNEST Partners
30
EARNEST Partners
Georgia
$165M -$2.32M -29,796 -1%
Invesco
31
Invesco
Georgia
$163M -$30.6M -392,993 -16%
Point72 Asset Management
32
Point72 Asset Management
Connecticut
$133M +$46.3M +594,608 +52%
Capital Research Global Investors
33
Capital Research Global Investors
California
$133M
Royal Bank of Canada
34
Royal Bank of Canada
Ontario, Canada
$130M +$4.69M +60,232 +4%
RJA
35
Raymond James & Associates
Florida
$130M +$3.65M +46,875 +3%
Neuberger Berman Group
36
Neuberger Berman Group
New York
$128M +$103M +1,324,343 +386%
Capital International Investors
37
Capital International Investors
California
$126M +$78 +1 +0%
Goldman Sachs
38
Goldman Sachs
New York
$122M +$4.59M +58,989 +4%
SEI Investments
39
SEI Investments
Pennsylvania
$112M +$2.39M +30,670 +2%
Rockefeller Capital Management
40
Rockefeller Capital Management
New York
$107M +$3.41M +43,797 +3%
Principal Financial Group
41
Principal Financial Group
Iowa
$98.6M +$6.85M +87,982 +7%
AG
42
Aperio Group
California
$94.6M +$12M +153,892 +14%
Ameriprise
43
Ameriprise
Minnesota
$89.8M +$5.74M +73,767 +7%
BCPEM
44
Bain Capital Public Equity Management
Massachusetts
$89.3M +$14.9M +191,651 +20%
Natixis Advisors
45
Natixis Advisors
Massachusetts
$86.7M +$10.4M +134,221 +14%
JP Morgan Chase
46
JP Morgan Chase
New York
$85.7M +$38.1M +489,263 +78%
Macquarie Group
47
Macquarie Group
Australia
$79.3M -$726K -9,324 -0.9%
Fiera Capital (Canada)
48
Fiera Capital (Canada)
Quebec, Canada
$78.2M -$1.08M -13,828 -1%
SI
49
Scharf Investments
California
$76.8M +$7.56M +97,061 +11%
CCM
50
Cullen Capital Management
New York
$74.2M -$2.22M -28,463 -3%

NVS Hedge Fund Activity: Q4 2018 in Review

1,087 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Novartis (NVS) for Q4 2018, worth a combined $23.4B — up 4.4% from $22.4B a quarter earlier.

Buyers outnumbered sellers: 143 funds opened new NVS positions and 76 closed out — a net gain of 67 holders — while 342 added to existing stakes and 403 trimmed.

The largest buyer was BlackRock, adding an estimated $687M. The largest seller was Dodge & Cox, cutting an estimated $657M.

  • 1,087 institutional investors held Novartis (NVS) as of Q4 2018, up from 1,028 in Q3 2018.
  • Funds reported $23.4B of Novartis stock for Q4 2018, up 4.4% quarter-over-quarter.
  • 143 funds opened new Novartis positions in Q4 2018 and 76 closed out, a net change of +67 holders.
  • The largest Novartis buyer in Q4 2018 was BlackRock, an estimated $687M added.
  • The largest Novartis seller in Q4 2018 was Dodge & Cox, an estimated $657M sold.

Based on aggregated 13F filings for Q4 2018.